MBX Biosciences is trading at $60.27 (down 4.2%) today. The decline follows a downgrade by Wall Street Zen from a "hold" to a "sell" rating issued on Monday.
- This comes after a recent multi-day rally driven by positive May data for the MBX 4291 obesity portfolio and a Stifel price-target increase to $56.
- The company also recently navigated a CEO transition on July 13, which added to recent volatility.
- While previous momentum was strong, today's specific downgrade presents a fresh company-specific catalyst for the stock's pullback.